Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials
Phase meta-analysisN = 700
- Population
- Patients with carcinoma in situ of the bladder in nine randomised trials.
- Design
- Meta-analysis of published randomised trials comparing intravesical BCG with intravesical chemotherapy (mitomycin C, epirubicin, adriamycin or sequential mitomycin C/adriamycin) in carcinoma in situ: nine trials, 700 patients.
- Arms
- Intravesical BCG (experimental): Intravesical BCG
- Intravesical chemotherapy (control): Intravesical mitomycin C, epirubicin, adriamycin or sequential mitomycin C/adriamycin
- People
- Sylvester RJ
Δ Complete response in carcinoma in situ+16.6 pointsΔ No evidence of disease at follow-up+20.5 points
Show the numbers
| Endpoint | Analysis | Intravesical BCG | Intravesical chemotherapy | Effect |
|---|---|---|---|---|
| Complete response in carcinoma in situPooled patients with carcinoma in situ and response data | finalSylvester 2005 | 68.1% | 51.5% | P=0.0002203 of 298 versus 158 of 307. The abstract gives a 47% reduction in the odds of nonresponse on BCG (odds ratio 0.53) without a confidence interval. |
| No evidence of disease at follow-upPooled patients with carcinoma in situ and long-term follow-up | finalmedian follow-up 3.6 yearsSylvester 2005 | 46.7% | 26.2% | P<0.0001161 of 345 versus 93 of 355; a 59% reduction in the odds of treatment failure on BCG (odds ratio 0.41; no confidence interval in the abstract). The abstract states the long-term benefit of BCG was smaller in trials with mitomycin C, and that BCG was superior to mitomycin C in trials with maintenance BCG (OR 0.57, p = 0.04). |
| Endpoint | Analysis | Intravesical BCG | Intravesical chemotherapy | Effect |
|---|---|---|---|---|
| Complete response in carcinoma in situPooled patients with carcinoma in situ and response data | finalSylvester 2005 | 68.1% | 51.5% | P=0.0002203 of 298 versus 158 of 307. The abstract gives a 47% reduction in the odds of nonresponse on BCG (odds ratio 0.53) without a confidence interval. |
| No evidence of disease at follow-upPooled patients with carcinoma in situ and long-term follow-up | finalmedian follow-up 3.6 yearsSylvester 2005 | 46.7% | 26.2% | P<0.0001161 of 345 versus 93 of 355; a 59% reduction in the odds of treatment failure on BCG (odds ratio 0.41; no confidence interval in the abstract). The abstract states the long-term benefit of BCG was smaller in trials with mitomycin C, and that BCG was superior to mitomycin C in trials with maintenance BCG (OR 0.57, p = 0.04). |
Appears in
Sources
Sylvester RJ, van der Meijden AP, Witjes JA, Kurth K. Bacillus calmette-guerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: a meta-analysis of the published results of randomized clinical trials. J Urol. 2005;174(1):86-91; discussion 91-2.